Ms. Reinhart is the former chief trial counsel for the Federal Trade Commission Bureau of Competition. While there, she led FTC trial teams through two preliminary injunction proceedings, and prepared for litigation in many other merger investigations, including RJ Reynolds-Lorillard, Zillow-Trulia, St. Mary’s Hospital-Cabell Hospital and Superior Plus-Canexus, among others. Notably, she led a team to victory in the FTC’s challenge to Staples’ proposed acquisition of Office Depot, one of the FTC’s highest-profile merger litigation successes in over a decade. Since returning to Skadden, Ms. Reinhart has led trial teams in two Department of Justice Antitrust Division merger challenges, including a win on behalf of Sabre Corporation in 2020. In 2022, Ms. Reinhart again successfully represented Sabre in a three-week jury trial victory in an action brought by US Airways alleging violations of sections 1 and 2 of the Sherman Act.
In private practice in the government investigations area, Ms. Reinhart has handled criminal and civil investigations by the Department of Justice’s Antitrust Division, the FTC and state attorneys general in many industries. She represents companies and individuals in FTC investigations into alleged violations of Section 5(a) of the FTC Act for unfair advertising and marketing practices, such as allegations of deceptive online advertising, negative option marketing and multi-level marketing. Ms. Reinhart has handled criminal antitrust investigations for companies and individuals in pharmaceuticals, auto parts, freight forwarding, marine hose, air cargo, helicopter transportation, industrial chemicals, methionine, vitamins, graphite electrodes, flavorants and stay cable bridges industries.
In the litigation area, Ms. Reinhart has handled many class actions alleging price-fixing for companies such as Anheuser Busch, Hankyu Hanshin Express, Norfolk Southern Railway Company, Southeastern Freight Lines, Korean Air Lines, Degussa and others. She has handled a number of private actions alleging monopolization and conspiracy to monopolize, including claims of reverse payments agreements for pharmaceutical companies.
In 2022, Ms. Reinhart was named to Chambers USA, in which clients noted that she is “very talented at working through issues strategically and tactically.”